Biotechnology Center, School of Life Science and Technology, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, China.
Appl Microbiol Biotechnol. 2012 Mar;93(5):1937-45. doi: 10.1007/s00253-011-3726-0. Epub 2011 Dec 2.
Epitope vaccine based on urease of Helicobacter pylori is a promising option for prophylactic and therapeutic vaccination against H. pylori infection. In this study, we constructed an epitope vaccine with mucosal adjuvant cholera toxin B subunit (CTB) and an epitope (UreA(183-203)) of H. pylori urease A subunit named CTB-UA. The CTB-UA fusion protein was expressed in Escherichia coli, and the purified protein was used for intraperitoneal immunization experiments in BALB/c mice. The experimental results indicated that anti-CTB-UA antibody could recognize both H. pylori urease A subunit (UreA) and urease B subunit (UreB). Besides, the CTB-UA epitope vaccine had good immunogenicity and immunoreactivity and could induce specific neutralizing antibodies which showed effectively inhibitory effect on the enzymatic activity of H. pylori urease. CTB-UA is a promising molecule to be investigated as H. pylori vaccine antigen candidate.
基于幽门螺杆菌脲酶的表位疫苗是预防和治疗幽门螺杆菌感染的有前途的选择。在这项研究中,我们构建了一种黏膜佐剂霍乱毒素 B 亚单位(CTB)和幽门螺杆菌脲酶 A 亚单位表位(UreA(183-203))的表位疫苗,命名为 CTB-UA。CTB-UA 融合蛋白在大肠杆菌中表达,纯化后的蛋白用于 BALB/c 小鼠的腹腔免疫实验。实验结果表明,抗-CTB-UA 抗体既能识别幽门螺杆菌脲酶 A 亚单位(UreA),也能识别脲酶 B 亚单位(UreB)。此外,CTB-UA 表位疫苗具有良好的免疫原性和免疫反应性,能诱导特异性中和抗体,对幽门螺杆菌脲酶的酶活性具有有效的抑制作用。CTB-UA 是一种很有前途的分子,可以作为幽门螺杆菌疫苗抗原候选物进行研究。